149 related articles for article (PubMed ID: 37747431)
21. Prognostic value of testosterone for the castration-resistant prostate cancer patients: a systematic review and meta-analysis.
Miura N; Mori K; Mostafaei H; Quhal F; Sari Motlagh R; Abufaraj M; Pradere B; Aydh A; Laukhtina E; D'Andrea D; Saika T; Shariat SF
Int J Clin Oncol; 2020 Nov; 25(11):1881-1891. PubMed ID: 32681382
[TBL] [Abstract][Full Text] [Related]
22. Tissue- and Blood-derived Genomic Biomarkers for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review.
Van der Eecken K; Vanwelkenhuyzen J; Deek MP; Tran PT; Warner E; Wyatt AW; Kwan EM; Verbeke S; Van Dorpe J; Fonteyne V; Lumen N; De Laere B; Ost P
Eur Urol Oncol; 2021 Dec; 4(6):914-923. PubMed ID: 34801437
[TBL] [Abstract][Full Text] [Related]
23. Genomic profiles and clinical outcomes in primary versus secondary metastatic hormone-sensitive prostate cancer.
Nizialek E; Lim SJ; Wang H; Isaacsson Velho P; Yegnasubramanian S; Antonarakis ES
Prostate; 2021 Jun; 81(9):572-579. PubMed ID: 33955569
[TBL] [Abstract][Full Text] [Related]
24. Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis.
Yanagisawa T; Rajwa P; Thibault C; Gandaglia G; Mori K; Kawada T; Fukuokaya W; Shim SR; Mostafaei H; Motlagh RS; Quhal F; Laukhtina E; Pallauf M; Pradere B; Kimura T; Egawa S; Shariat SF
Eur Urol; 2022 Dec; 82(6):584-598. PubMed ID: 35995644
[TBL] [Abstract][Full Text] [Related]
25. Does Baseline Serum Testosterone Influence Androgen Deprivation Therapy Outcomes in Hormone Naïve Patients with Advanced Prostate Cancer?
Patel A
J Urol; 2021 Mar; 205(3):806-811. PubMed ID: 33035140
[TBL] [Abstract][Full Text] [Related]
26. [Current status of androgen deprivation therapy in hormone-sensitive prostate cancer.].
Alvarez Rodríguez S; Alonso Gordoa T; Burgos Revilla FJ
Arch Esp Urol; 2018 Mar; 71(3):247-257. PubMed ID: 29633945
[TBL] [Abstract][Full Text] [Related]
27. Hormone naïve prostate cancer: predicting and maximizing response intervals.
Moul JW
Asian J Androl; 2015; 17(6):929-35; discussion 933. PubMed ID: 26112479
[TBL] [Abstract][Full Text] [Related]
28. Serum testosterone measured by liquid chromatography-tandem mass spectrometry is an independent predictor of response to castration in metastatic hormone-sensitive prostate cancer.
van Winden LJ; Lanfermeijer M; Dezentje V; Bergman AM; van der Poel HG; van Rossum HH
Clin Chim Acta; 2023 Jan; 539():34-40. PubMed ID: 36460134
[TBL] [Abstract][Full Text] [Related]
29. The Prognostic Significance of Homologous Recombination Repair Pathway Alterations in Metastatic Hormone Sensitive Prostate Cancer.
Lee AM; Saidian A; Shaya J; Nonato T; Cabal A; Randall JM; Millard F; Stewart T; Rose B; Tamayo P; McKay RR
Clin Genitourin Cancer; 2022 Dec; 20(6):515-523. PubMed ID: 35871039
[TBL] [Abstract][Full Text] [Related]
30. Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer.
Goodman OB; Symanowski JT; Loudyi A; Fink LM; Ward DC; Vogelzang NJ
Clin Genitourin Cancer; 2011 Sep; 9(1):31-8. PubMed ID: 21705286
[TBL] [Abstract][Full Text] [Related]
31. Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis.
Fallara G; Robesti D; Nocera L; Raggi D; Marandino L; Belladelli F; Montorsi F; Malavaud B; Ploussard G; Necchi A; Martini A
Cancer Treat Rev; 2022 Nov; 110():102441. PubMed ID: 35939976
[TBL] [Abstract][Full Text] [Related]
32. Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients.
Vermunt MAC; van Nuland M; van der Heijden LT; Rosing H; Beijnen JH; Bergman AM
Cancer Chemother Pharmacol; 2022 Jun; 89(6):785-793. PubMed ID: 35467095
[TBL] [Abstract][Full Text] [Related]
33. Correlation Between Trough Level of Abiraterone and Prostate-Specific Antigen (PSA) Response in Metastatic Hormone-Sensitive Prostate Cancer.
Myint ZW; Kolesar JM; McCorkle JR; Wu J; Ellis CS; Otto DE; Wang P
Med Sci Monit; 2022 Oct; 28():e938091. PubMed ID: 36229939
[TBL] [Abstract][Full Text] [Related]
34. Use of classical and novel biomarkers as prognostic risk factors for localised prostate cancer: a systematic review.
Sutcliffe P; Hummel S; Simpson E; Young T; Rees A; Wilkinson A; Hamdy F; Clarke N; Staffurth J
Health Technol Assess; 2009 Jan; 13(5):iii, xi-xiii 1-219. PubMed ID: 19128541
[TBL] [Abstract][Full Text] [Related]
35. Variations in circulating sex steroid levels in metastatic prostate cancer patients with combined androgen blockade: observation and implication.
Qin X; Zhang H; Ye D; Yao X; Zhang S; Dai B
Andrology; 2013 May; 1(3):512-6. PubMed ID: 23536478
[TBL] [Abstract][Full Text] [Related]
36. The Health Economics of Metastatic Hormone-Sensitive and Non-Metastatic Castration-Resistant Prostate Cancer-A Systematic Literature Review with Application to the Canadian Context.
Yanev I; Gatete J; Aprikian AG; Guertin JR; Dragomir A
Curr Oncol; 2022 May; 29(5):3393-3424. PubMed ID: 35621665
[No Abstract] [Full Text] [Related]
37. Treatments for Metastatic Hormone-sensitive Prostate Cancer: Systematic Review, Network Meta-analysis, and Benefit-harm assessment.
Menges D; Yebyo HG; Sivec-Muniz S; Haile SR; Barbier MC; Tomonaga Y; Schwenkglenks M; Puhan MA
Eur Urol Oncol; 2022 Dec; 5(6):605-616. PubMed ID: 35599144
[TBL] [Abstract][Full Text] [Related]
38. Methods for Evaluating the Efficacy of Medical Castration: A Systematic Review.
Aguilar A; Planas J; Trilla E; Morote J
Cancers (Basel); 2023 Jul; 15(13):. PubMed ID: 37444589
[TBL] [Abstract][Full Text] [Related]
39. Should we follow-up serum testosterone in patients with advanced prostate cancer?
Perachino M
Expert Rev Anticancer Ther; 2010 Jul; 10(7):1031-5. PubMed ID: 20645692
[TBL] [Abstract][Full Text] [Related]
40. Both High and Low Serum Total Testosterone Levels Indicate Poor Prognosis in Patients with Prostate Cancer.
Izumi K; Shigehara K; Nohara T; Narimoto K; Kadono Y; Mizokami A
Anticancer Res; 2017 Oct; 37(10):5559-5564. PubMed ID: 28982870
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]